Literature DB >> 3016312

Herpes simplex virus (HSV)-specific human T-cell clones recognize HSV glycoprotein D expressed by a recombinant vaccinia virus.

J M Zarling, P A Moran, L A Lasky, B Moss.   

Abstract

Human cytotoxic T-cell (CTL) clones that lyse autologous cells infected with herpes simplex virus (HSV) type 1 or 2 were generated by stimulating lymphocytes with a recombinant vaccinia virus (recombinant vaccinia-gD-1 virus) that expresses HSV type 1 glycoprotein D (gD-1). Furthermore, CTL clones generated with HSV type 1 or with cloned gD-1 lysed autologous cells infected with the recombinant vaccinia-gD-1 virus. Our findings thus showed that gD serves as a target antigen for human CTLs and that a recombinant vaccinia-gD virus activates HSV-specific human CTL.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3016312      PMCID: PMC253104     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Role for cell-mediated immunity in the resistance of mice to subcutaneous herpes simplex virus infection.

Authors:  J E Oakes
Journal:  Infect Immun       Date:  1975-07       Impact factor: 3.441

2.  Mechanism of acquired resistance to herpes simplex virus infection as studied in nude mice.

Authors:  S Nagafuchi; H Oda; R Mori; T Taniguchi
Journal:  J Gen Virol       Date:  1979-09       Impact factor: 3.891

3.  Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD.

Authors:  J M Zarling; P A Moran; R L Burke; C Pachl; P W Berman; L A Lasky
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

Review 4.  Infection with herpes-simplex viruses 1 and 2. 3.

Authors:  A J Nahmias; B Roizman
Journal:  N Engl J Med       Date:  1973-10-11       Impact factor: 91.245

5.  Serological analysis of herpes simplex virus types 1 and 2 with monoclonal antibodies.

Authors:  L Pereira; D V Dondero; D Gallo; V Devlin; J D Woodie
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

6.  Cell-mediated immunity in herpes simplex virus-infected mice: H-2 mapping of the delayed-type hypersensitivity response and the antiviral T cell response.

Authors:  A A Nash; J Phelan; P Wildy
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

7.  The involvement of herpes simplex virus type 1 glycoproteins in cell-mediated immunity.

Authors:  V C Carter; P A Schaffer; S S Tevethia
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

8.  Pathogenesis of herpes simplex virus in congenitally athymic mice: the relative roles of cell-mediated and humoral immunity.

Authors:  A K Kapoor; A A Nash; P Wildy; J Phelan; C S McLean; H J Field
Journal:  J Gen Virol       Date:  1982-06       Impact factor: 3.891

9.  Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virus-specific and H-2-restricted cytotoxic T lymphocytes.

Authors:  K K Sethi; Y Omata; K E Schneweis
Journal:  J Gen Virol       Date:  1983-02       Impact factor: 3.891

10.  Cell-mediated immunity to herpes simplex virus: specificity of cytotoxic T cells.

Authors:  M J Lawman; R J Courtney; R Eberle; P A Schaffer; M K O'Hara; B T Rouse
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

View more
  22 in total

1.  Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells.

Authors:  C C Marchioli; R J Yancey; E A Petrovskis; J G Timmins; L E Post
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  Varicella-zoster virus-specific cytotoxic T lymphocytes (Tc): detection and frequency analysis of HLA class I-restricted Tc in human peripheral blood.

Authors:  J K Hickling; L K Borysiewicz; J G Sissons
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

3.  Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells.

Authors:  R Khanna; C A Jacob; S R Burrows; M G Kurilla; E Kieff; I S Misko; T B Sculley; D J Moss
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

4.  Antigenic analysis of a major neutralization site of herpes simplex virus glycoprotein D, using deletion mutants and monoclonal antibody-resistant mutants.

Authors:  M I Muggeridge; V J Isola; R A Byrn; T J Tucker; A C Minson; J C Glorioso; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

Review 5.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

6.  Fine mapping of antigenic site II of herpes simplex virus glycoprotein D.

Authors:  V J Isola; R J Eisenberg; G R Siebert; C J Heilman; W C Wilcox; G H Cohen
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

Review 7.  Distinguishable pathways of viral antigen presentation to T lymphocytes.

Authors:  L A Morrison; V L Braciale; T J Braciale
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

8.  Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals.

Authors:  P X Guo; S Goebel; S Davis; M E Perkus; B Languet; P Desmettre; G Allen; E Paoletti
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

9.  Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D.

Authors:  Xiuli Zhang; Florence A Castelli; Xiaoming Zhu; Michele Wu; Bernard Maillère; Lbachir BenMohamed
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

10.  Constitutively expressing cell lines that secrete a truncated bovine herpes virus-1 glycoprotein (gpI) stimulate T-lymphocyte responsiveness.

Authors:  T P Leary; Y Gao; G A Splitter
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.